Table 3.
Comparison of immune responses after administration of 13-valent pneumococcal conjugate vaccine (PCV13).
| Serotype | Parameters of immunogenicity | Group 1 (N = 34) | Group 2 (N = 33) | p-value |
|---|---|---|---|---|
| 5 | Seroprotection rate (%) | 27 (79.4) | 17 (51.5) | 0.021 |
| Seroconversion rate (%) | 31 (91.2) | 25 (75.8) | 0.109 | |
| GMT fold increase (95% CI) | 72.9 (35.8– 148.3) | 18.3 (7.7–43.5) | 0.053 | |
| 6B | Seroprotection rate (%) | 34 (100) | 29 (87.9) | 0.053 |
| Seroconversion rate (%) | 25 (73.5) | 20 (60.6) | 0.305 | |
| GMT fold increase (95% CI) | 99.5 (30.8–321.7) | 20.5 (5.2–80.9) | 0.088 | |
| 18C | Seroprotection rate (%) | 32 (94.1) | 25 (75.8) | 0.045 |
| Seroconversion rate (%) | 26 (76.5) | 20 (60.6) | 0.194 | |
| GMT fold increase (95% CI) | 11.3 (6.5–19.9) | 5.9 (3.0–11.8) | 0.650 | |
| 19A | Seroprotection rate (%) | 34 (100) | 31 (93.9) | 0.239 |
| Seroconversion rate (%) | 29 (85.3) | 25 (75.8) | 0.369 | |
| GMT fold increase (95% CI) | 41.3 (17.2–98.8) | 17.8 (6.6–48.0) | 0.956 |
CI, confidence interval; GMT, geometric mean titer.
Group 1: HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL.
Group 2: HIV-infected subjects with CD4 T-cell counts <350 cells/µL.